title: Comparison of the efficacy and safety of irbesartan and olmesartan in patients with hypertension (EARTH study).
abstract: Fifty-four patients were randomly divided into irbesartan and olmesartan groups. Blood pressure (BP) was significantly decreased in all patients at 12 weeks. In particular, BP in patients who initially received irbesartan showed significant reductions. The equality of variance of BP in the irbesartan group was significantly smaller than that in the olmesartan group at 12 weeks. Blood concentrations of adiponectin were significantly increased in the irbesartan group at 12 weeks. Log [pentraxin-3] in the irbesartan group were significantly decreased. In conclusion, the ability of irbesartan to reduce BP is comparable to that of olmesartan with equivalent safety.
authors.affiliation: Department of Cardiology, Fukuoka University School of Medicine, Jonan-ku, Fukuoka, Japan.
authors.forename: Joji
authors.initials: J
authors.lastname: Morii
authors.forename: Shin-ichiro
authors.initials: S
authors.lastname: Miura
authors.forename: Yuhei
authors.initials: Y
authors.lastname: Shiga
authors.forename: Makoto
authors.initials: M
authors.lastname: Sugihara
authors.forename: Tadaaki
authors.initials: T
authors.lastname: Arimura
authors.forename: Hideto
authors.initials: H
authors.lastname: Sako
authors.forename: Bo
authors.initials: B
authors.lastname: Zhang
authors.forename: Yoshinari
authors.initials: Y
authors.lastname: Uehara
authors.forename: Keijiro
authors.initials: K
authors.lastname: Saku
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D047228:Angiotensin II Type 1 Receptor Blockers / Q000009:adverse effects / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001713:Biphenyl Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007093:Imidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D000077405:Irbesartan; D008297:Male; D008875:Middle Aged; D013777:Tetrazoles / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D001713:Biphenyl Compounds; D007093:Imidazoles; D013777:Tetrazoles; C437965:olmesartan; D000077405:Irbesartan